Search
Milestone Pharmaceuticals Inc
MISTAdd to Watchlist
1.159USD
-0.041-3.44%
Close 07-24 16:00（ET）Quotes delayed by 15 min
136.49MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Milestone Pharmaceuticals Inc is 8.00, ranking 168 out of 386 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 2.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
6.333
Target Price
+414.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Milestone Pharmaceuticals Inc
MIST
6
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Milestone Pharmaceuticals Inc's expected revenue for the next quarter?
Milestone Pharmaceuticals Inc's expected revenue is 933.33K.
What is Milestone Pharmaceuticals Inc's price target?
Analysts forecast that Milestone Pharmaceuticals Inc's price target is USD 4.00, with the highest forecast at USD 5.00 and the lowest forecast at USD 2.00.
How have Milestone Pharmaceuticals IncMIST's recent earnings per share performed?
The market expectation was USD -0.20, while Milestone Pharmaceuticals IncMIST's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for Milestone Pharmaceuticals Inc?
Based on the ratings of Milestone Pharmaceuticals Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.